Feeling a Little Better

Still in the hospital.  My temperature seems to have stabilized near normal, I'm coughing a little less, and blood oxygen (without supplemental oxygen) is up in the 94% range.  However, pulse rate and respiration rate are unchanged and much higher than normal, so the jury is still out. For the medically inclined:  I was started on a Z-Pak (azithromycin) Monday, then in the hospital they added a cephalosporin IV antibiotic Tuesday.  By today (Thursday) we didn't see much progress, so the hospital doctor finally talked me into oral Levaquin, dropping both of the others. That dose was this noon , so it's had only about nine hours to take effect, and obviously I don't know which antibiotic regimen might be working, if indeed anything really is working. I'm nervous about Levaquin, because it's one of the drugs that can cause the Achilles tendon to rupture.  If that happens my running will be dramatically curtailed (zero).  However I finally agreed to Levaquin because I didn't see progress on the other meds, and I can live without running but I can't run without living. As always, I'll know more in the morning.  I'm still alive and there is a little more light at the end of the tunnel.
Source: Myeloma Hope - Category: Cancer Tags: pneumonia Source Type: blogs

Related Links:

CONCLUSIONS: This study provides the basis for studying the addition of JAK inhibitors to improve the efficacy of immunomodulatory agents with steroids for treating myeloma patients but perhaps can also be expanded for treating other cancer patients that are refractory to this class of drugs. PMID: 31937615 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Diffuse alveolar hemorrhage (DAH) may occur with vasculitis, infection, and coagulation disorders. In patients with hematologic malignancies such as leukemia, lymphoma and multiple myeloma, the risk of death from DAH is 70%. Although their effectiveness remains uncertain, corticosteroids are the mainstay of treatment. It is not easy to determine the use of corticosteroids because of the adverse effects such as worsening of infections, gastrointestinal (GI) bleeding and poor blood glucose control. Retrospective analysis was performed at a single medical center in South Korea from August 2005 to April 2018. DAH was diagnosed...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Rare ILD/DPLD Source Type: research
Publication date: Available online 14 November 2019Source: The LancetAuthor(s): Michel Attal, Paul G Richardson, S Vincent Rajkumar, Jesus San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A Dimopoulos, Jeffrey Shang-Yi Huang, Jiri Minarik, Michele Cavo, H Miles Prince, Sandrine Macé, Kathryn P Corzo, Frank Campana, Solenn Le-Guennec, Franck Dubin, Kenneth C AndersonSummaryBackgroundIsatuximab is a monoclonal antibody that binds a specific epitope on the human CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous phase 1b study, ar...
Source: The Lancet - Category: General Medicine Source Type: research
In conclusion, D-VMP was safe and efficacious in East Asian patients, consistent with the global ALCYONE population.
Source: Annals of Hematology - Category: Hematology Source Type: research
ConclusionIn this meta-analysis, ibrutinib was associated with significantly higher risk of infections in patients with B-cell malignancies. Occurrence of major individual subtypes was not different between groups, possibly due to inconsistent reporting across studies.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Infections are the major cause of morbidity and mortality after high-dose therapy with melphalan followed by autologous blood stem cell transplantation (HDT/ABSCT) in multiple myeloma (MM). Therefore, there is a need for effective anti-infective strategies like antibiotic prophylaxis (AB-P) or Granulocyte colony stimulating factor (G-CSF) support. Given the increasing prevalence of multidrug resistant (MDR) bacteria, AB-P with ciprofloxacin or cotrimoxazole twice a day was stopped in January 2017 at our transplantation center and replaced by G-CSF support and Pneumocystis jirovecii pneumonia (PCP) prophylaxis with cotrimox...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
CONCLUSION: CART-related GI-AEs occur in 15% of patients treated with CART. These symptoms are typically mild and self-limiting, requiring only symptomatic treatment. Nevertheless, CART may, in rare cases, lead to refractory colitis. PMID: 31478934 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: Am J Clin Oncol Source Type: research
Publication date: Available online 18 July 2019Source: The Lancet HaematologyAuthor(s): Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo, Robert M Rifkin, Habte Aragaw Yimer, Richard LeBlanc, Naoki Takezako, Robert Donald McCroskey, Andrew Boon Ming Lim, Kenshi Suzuki, Hiroshi Kosugi, George Grigoriadis, Irit Avivi, Thierry Facon, Sundar Jagannath, Sagar Lonial, Razi Uddin Ghori, Mohammed Z H FarooquiSummaryBackgroundLenalidomide and dexamethasone has been a standard of care in transplant-ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to the combinati...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Publication date: Available online 17 July 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Fernando Cabanillas, Noridza Rivera, Mirelis Acosta, Wandaly Pardo, Pedro Solivan, Caroline Rivera, Idalia LiboyAbstractBackgroundOur objective was to evaluate the impact of lenalidomide in patients with aggressive lymphoma who attained
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This phase 1b dose-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Patients who had received ≥2 prior MM therapies, including lenalidomide and a proteasome inhibitor (PI), were enrolled and received isatuximab at 5, 10, or 20 mg/kg (weekly for 4 weeks, followed by every 2 weeks), pomalidomide 4 mg (days 1-21), and dexamethasone 40 mg (weekly) in 28-day cycles until progression/intolerable toxicity. The primary objective was to determine the safety and recommended dose of isatuximab with this combination. Secondary objectives included eva...
Source: Blood - Category: Hematology Authors: Tags: Multiple Myeloma, Lymphoid Neoplasia, Clinical Trials and Observations Source Type: research
More News: Azithromycin | Hospitals | Levaquin | Myeloma | Pneumonia | Zithromax